1. Home
  2. GPRO vs CHRS Comparison

GPRO vs CHRS Comparison

Compare GPRO & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GoPro Inc.

GPRO

GoPro Inc.

HOLD

Current Price

$1.30

Market Cap

119.4M

ML Signal

HOLD

Logo Coherus BioSciences Inc.

CHRS

Coherus BioSciences Inc.

HOLD

Current Price

$1.30

Market Cap

177.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GPRO
CHRS
Founded
2004
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
119.4M
177.7M
IPO Year
2014
2014

Fundamental Metrics

Financial Performance
Metric
GPRO
CHRS
Price
$1.30
$1.30
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$5.51
AVG Volume (30 Days)
70.1M
876.3K
Earning Date
05-11-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
79.08
472.00
EPS
N/A
N/A
Revenue
$651,542,000.00
N/A
Revenue This Year
$23.14
$73.08
Revenue Next Year
N/A
$30.94
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.57
$1.09
52 Week High
$3.05
$2.62

Technical Indicators

Market Signals
Indicator
GPRO
CHRS
Relative Strength Index (RSI) 57.87 46.05
Support Level $0.65 N/A
Resistance Level $1.70 $1.51
Average True Range (ATR) 0.26 0.08
MACD -0.01 -0.01
Stochastic Oscillator 47.23 43.14

Price Performance

Historical Comparison
GPRO
CHRS

About GPRO GoPro Inc.

GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts and accessories, lifestyle gear, applications, and subscriptions and services. The company sells products across the world through retailers, distributors, and on GoPro.com. Its hardware products are designed and developed in the United States, France, China, and Romania, and a majority of the manufacturing is outsourced to contract manufacturers located in China, Thailand, and Vietnam. Geographically, the company generates maximum revenue from the Americas, followed by Europe, Middle East and Africa (EMEA), and Asia and Pacific (APAC) region.

About CHRS Coherus BioSciences Inc.

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.

Share on Social Networks: